See more : McDonald’s Corporation (MCD) Income Statement Analysis – Financial Results
Complete financial analysis of 2seventy bio, Inc. (TSVT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 2seventy bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ACNB Corporation (ACNB) Income Statement Analysis – Financial Results
- Church & Crawford, Inc. (CCWF) Income Statement Analysis – Financial Results
- Medcomtech, S.A. (MED.MC) Income Statement Analysis – Financial Results
- Shandong Hi-Speed Road and Bridge Group Co., Ltd. (000498.SZ) Income Statement Analysis – Financial Results
- Impact Healthcare REIT PLC (IHR.L) Income Statement Analysis – Financial Results
2seventy bio, Inc. (TSVT)
About 2seventy bio, Inc.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 100.39M | 91.50M | 54.52M | 248.12M | 44.30M | 54.58M |
| Cost of Revenue | 16.92M | 26.22M | 12.59M | 5.40M | 2.98M | 885.00K |
| Gross Profit | 83.47M | 65.28M | 41.93M | 242.73M | 41.32M | 53.69M |
| Gross Profit Ratio | 83.15% | 71.34% | 76.91% | 97.83% | 93.28% | 98.38% |
| Research & Development | 230.76M | 248.74M | 261.94M | 296.47M | 297.65M | 200.49M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 69.41M | 79.45M | 93.51M | 90.90M | 81.65M | 53.63M |
| Other Expenses | 20.91M | 6.06M | 21.65M | 18.06M | 20.13M | 19.16M |
| Operating Expenses | 321.08M | 328.19M | 355.44M | 387.36M | 379.29M | 254.12M |
| Cost & Expenses | 317.09M | 354.40M | 368.03M | 392.76M | 382.27M | 255.01M |
| Interest Income | 12.41M | 2.93M | 88.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.49M |
| Depreciation & Amortization | 10.29M | 11.53M | 16.40M | 13.19M | 12.59M | 13.35M |
| EBITDA | -206.42M | -251.38M | -297.16M | -131.45M | -329.19M | -187.08M |
| EBITDA Ratio | -205.62% | -274.49% | -574.21% | -45.70% | -728.37% | -307.66% |
| Operating Income | -216.70M | -262.91M | -313.51M | -144.64M | -337.97M | -203.43M |
| Operating Income Ratio | -215.87% | -287.34% | -575.01% | -58.29% | -762.99% | -372.72% |
| Total Other Income/Expenses | -867.00K | 8.76M | 21.30M | 24.52M | 17.38M | 3.68M |
| Income Before Tax | -217.57M | -254.15M | -292.21M | -120.11M | -320.59M | -199.75M |
| Income Before Tax Ratio | -216.73% | -277.77% | -535.95% | -48.41% | -723.75% | -365.98% |
| Income Tax Expense | 0.00 | -8.99K | -16.00M | 18.06M | 2.75M | 19.16M |
| Net Income | -217.57M | -254.14M | -276.21M | -138.17M | -323.34M | -199.75M |
| Net Income Ratio | -216.73% | -277.77% | -506.61% | -55.69% | -729.96% | -365.98% |
| EPS | -4.42 | -7.13 | -11.71 | -5.93 | -13.88 | -8.58 |
| EPS Diluted | -4.42 | -7.13 | -11.71 | -5.93 | -13.88 | -8.58 |
| Weighted Avg Shares Out | 49.28M | 35.64M | 23.59M | 23.29M | 23.29M | 23.29M |
| Weighted Avg Shares Out (Dil) | 49.28M | 35.64M | 23.59M | 23.29M | 23.29M | 23.29M |
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company's Board of...
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2023. “In the past weeks and months, 2seventy has...
Should You Buy 2seventy bio (TSVT) Ahead of Earnings?
2seventy bio (TSVT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT) will announce its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Members of the management...
2seventy bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will present at the following upcoming investor conferences: Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, the St. Regis New York, fireside chat on Thursday,...
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?
2seventy bio, Inc. (TSVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up
2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
2seventy bio Announces New Strategic Path Forward
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T therapy for multiple myeloma. The actions announced today follow...
All You Need to Know About 2seventy bio, Inc. (TSVT) Rating Upgrade to Strong Buy
2seventy bio, Inc. (TSVT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include DouYu International (DOYU), Regis (RGS), 2seventy bio Inc. (TSVT), atai Life Sciences (ATAI) and GameStop (GME).
Source: https://incomestatements.info
Category: Stock Reports